5-tert-butyl-pyridine-2-carboxylic acid amide | 68692-47-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-tert-butyl-pyridine-2-carboxylic acid amide
• 英文别名: 5-(tert-Butyl)picolinamide；5-tert-butylpyridine-2-carboxamide
• CAS: 68692-47-7
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: XVZKGEIQLVAGHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• IDO INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160289171A1

  公开（公告）日：2016-10-06

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶（IDO）的酶活性，含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• Compounds Which Modulate The CB2 Receptor
  申请人：Berry Angela

  公开号：US20100009964A1

  公开（公告）日：2010-01-14

  Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公式（I）的化合物已被披露。根据该公式的化合物对治疗炎症有用。那些是激动剂的化合物还额外适用于治疗疼痛。
• [EN] AMIDE DERIVATIVES AS BTK INHIBITORS IN THE TREATMENT OF ALLERGIC, AUTOIMMUNE AND INFLAMMATORY DISORDERS AS WELL AS CANCER<br/>[FR] DÉRIVÉS AMIDES UTILISÉS COMME INHIBITEURS DE LA BTK DANS LE TRAITEMENT DES AFFECTIONS ALLERGIQUES, AUTO-IMMUNES ET INFLAMMATOIRES ET DANS LE TRAITEMENT DU CANCER
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010068806A1

  公开（公告）日：2010-06-17

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的化合物。描述了包括至少一种化合物I的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗对Btk活性和/或B细胞活性抑制敏感的患者的方法。描述了检测样本中Btk存在的方法。
• IDO inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10167254B2

  公开（公告）日：2019-01-01

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  本发明公开了调节或抑制吲哚胺-2,3-二氧化酶（IDO）酶活性的化合物、含有上述化合物的药物组合物以及利用本发明化合物治疗增殖性疾病（如癌症、病毒感染和/或炎症性疾病）的方法。
• Inhibitors of BCR-ABL mutants and use thereof
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10196378B2

  公开（公告）日：2019-02-05

  Inhibitor compounds of Bcr-Abl and Bcr-Abl mutants including Bcr-Abl T315I mutant protein are disclosed. Compositions comprising the inhibitor compounds and methods of using the compounds in the treatment of leukemia such as chronic myelogenous leukemia are also disclosed.

  本研究公开了 Bcr-Abl 和 Bcr-Abl 突变体（包括 Bcr-Abl T315I 突变蛋白）的抑制剂化合物。还公开了包含抑制剂化合物的组合物以及使用这些化合物治疗白血病（如慢性骨髓性白血病）的方法。